Description
Anti-TNFSF12 Antibody, Non-Fucosylated (BioBet-478ZP) is a humanized and chimeric monoclonal IgG1, κ antibody against TNFSF12. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Solid tumors
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced TNFSF12 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TNFSF12
Full Name
TNFSF12 Gene(Protein Coding)
TNF Superfamily Member 12
Background
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein is a ligand for the FN14/TWEAKR receptor. This cytokine has overlapping signaling functions with TNF, but displays a much wider tissue distribution. This cytokine, which exists in both membrane-bound and secreted forms, can induce apoptosis via multiple pathways of cell death in a cell type-specific manner. This cytokine is also found to promote proliferation and migration of endothelial cells, and thus acts as a regulator of angiogenesis. Alternative splicing results in multiple transcript variants. Some transcripts skip the last exon of this gene and continue into the second exon of the neighboring TNFSF13 gene; such read-through transcripts are contained in GeneID 407977, TNFSF12-TNFSF13. [provided by RefSeq, Oct 2010]
Alternative Names
Enavatuzumab; 912628-39-8; PDL192; TNFSF12; tumor necrosis factor (ligand) superfamily, member 12; tumor necrosis factor ligand superfamily member 12; APO3L; DR3LG; TWEAK; APO3 ligand; APO3/DR3 ligand; TNF-related WEAK inducer of apoptosis; MGC20669; MGC129581;
Gene ID
8742
UniProt ID
O43508
Cellular Localization
Plasma membrane, Extracellular region or secreted
Involvement in Disease
Diseases associated with TNFSF12 include Common Variable Immunodeficiency and Amnestic Disorder.
Related Pathways
Its related pathways are Apoptosis Modulation and Signaling and PEDF Induced Signaling.
Function
It binds to FN14 and may also bind to TNRFSF12/APO3. Weakly induce some types of apoptosis. Mediates the activation of NF-kappa-B. Promote angiogenesis and endothelial cell proliferation. It is also involved in the induction of inflammatory cytokines. Promote IL8 secretion.
Post-translational modifications
1.The soluble form derives from the membrane form by proteolytic processing. 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn139
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
BioBet-478ZP
Description
ADCC-enhanced Enavatuzumab is a non-fucosylated anti-TNFSF12 therapeutic biobetter antibody.
Antibody Indication
Solid tumors
